Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹740 Cr
Revenue (TTM)
₹198 Cr
Net Profit (TTM)
₹26 Cr
ROE
8.4 %
ROCE
13.3 %
P/E Ratio
27.7
P/B Ratio
3.7
Industry P/E
39.04
EV/EBITDA
18.3
Div. Yield
0 %
Debt to Equity
0.1
Book Value
₹125.8
EPS
₹16.4
Face value
10
Shares outstanding
16,082,319
CFO
₹70.79 Cr
EBITDA
₹62.51 Cr
Net Profit
₹21.29 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kilitch Drugs
| 41.6 | 6.5 | 46.9 | 39.5 | 42.8 | 33.0 | 32.9 |
|
BSE Healthcare
| -3.5 | 2.7 | 10.9 | 16.8 | 26.9 | 22.0 | 10.8 |
|
BSE Small Cap
| -2.6 | 4.5 | 21.7 | 4.2 | 29.9 | 35.1 | 17.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Kilitch Drugs
| -11.4 | 137.3 | -37.6 | 146.7 | -24.0 | -21.1 | 79.7 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kilitch Drugs
|
462.0 | 739.8 | 198.3 | 24.6 | 14.1 | 13.4 | 27.7 | 3.7 |
| 701.0 | 2,031.3 | 451.8 | 50.8 | 11.4 | 16.3 | 40 | 6.2 | |
| 482.3 | 7,888.2 | 2,108.1 | 266.8 | 12.5 | 11.7 | 29.6 | 3.5 | |
| 370.4 | 3,739.9 | 819.8 | 69.7 | 13.9 | 11.9 | 53.7 | 6.2 | |
| 442.0 | 2,707.9 | 559.1 | -8.7 | -10.9 | -159 | -- | 3.2 | |
| 5,898.5 | 9,826.8 | 1,218.1 | 251.2 | 28.1 | -- | 39.1 | 18.3 | |
| 946.0 | 9,415.3 | 1,286.4 | 79.6 | 15.9 | 4.7 | 120.3 | 4.0 | |
| 881.0 | 8,173.9 | 4,632.7 | 358.2 | 14.8 | 15 | 2.3 | 3.2 | |
| 682.7 | 5,542.5 | 696.5 | 188.0 | 34.5 | 19.8 | 29.5 | 5.6 | |
| 20.3 | 1,917.6 | 466.0 | 49.4 | 10.7 | 15.1 | 38.8 | 5.6 |
No Review & Analysis are available.
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic,... anti-inflammatory, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, antifungals, corticosteroids, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, soft gelatin capsules, dry syrup, gripe water, and oral gel, powder, and liquid in the cardiovascular and anti-diabetics areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, and ROIVIT; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, creams, lotions, liquids, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India. Read more
Incorporated
1992
Chairman
--
Managing Director
Mukund P Mehta
Headquarters
Navi Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Kilitch Drugs (India) Ltd stood at ₹ 313 Cr as on 31-Mar-25
The share price of Kilitch Drugs (India) Ltd is ₹462.00 (NSE) and ₹467.00 (BSE) as of 17-Jun-2025 12:44 IST. Kilitch Drugs (India) Ltd has given a return of 42.79% in the last 3 years.
Kilitch Drugs (India) Ltd has a market capitalisation of ₹ 740 Cr as on 17-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Kilitch Drugs (India) Ltd is 3.66 times as on 17-Jun-2025, a 35% discount to its peers’ median range of 5.59 times.
The P/E ratio of Kilitch Drugs (India) Ltd is 27.71 times as on 17-Jun-2025, a 29% discount to its peers’ median range of 39.04 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Kilitch Drugs (India) Ltd and enter the required number of quantities and click on buy to purchase the shares of Kilitch Drugs (India) Ltd.
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-inflammatory, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, antifungals, corticosteroids, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, soft gelatin capsules, dry syrup, gripe water, and oral gel, powder, and liquid in the cardiovascular and anti-diabetics areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, and ROIVIT; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, creams, lotions, liquids, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
The prominent promoters of Kilitch Drugs (India) Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Kilitch Company (Pharma) Limited |
41.22%
|
|
Bhavin Mukund Mehta |
15.69%
|
|
Mukund Mehta |
7.09%
|
|
Mira Bhavin Mehta |
5.23%
|
The chairman of the company is , and the managing director is Mukund P Mehta.
There is no promoter pledging in Kilitch Drugs (India) Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
9,692
|
|
|
9,644
|
|
|
8,142
|
|
|
7,752
|
|
|
5,552
|
|
|
3,729
|
|
|
2,767
|
|
|
2,021
|
|
|
2,017
|
| Kilitch Drugs (India) Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
13.44
|
|
Operating margin(%)
|
14.1
|
|
Net Margin(%)
|
11.72
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Kilitch Drugs (India) Ltd was ₹26 Cr.
₹8.20
(
